GlassScriptPhysician profile
Pablo Alberto Urbandt
NPI 1851616783
$10,502.68
in general payments reported to CMS, 2019-2025
29 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,338 · 2020: $830 · 2021: $1,379 · 2022: $1,349 · 2023: $1,344 · 2024: $1,650 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,606.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,662.10 | 2019-2024 | Amplatzer Amulet, Aveir |
| Medtronic, INC. | $2,210.08 | 2022-2025 | Reveal Linq, Micra, Cobalt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $638.63 | 2019-2025 | |
| Boston Scientific Corporation | $469.76 | 2022-2025 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $448.75 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $385.06 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.58 | 2021-2025 | Jardiance |
| Pfizer INC. | $305.50 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $270.86 | 2019-2024 | Xarelto |
| Amgen INC. | $200.58 | 2021-2025 | Repatha, Repatha |
| Biosense Webster, INC. | $192.26 | 2021-2022 | |
| Cleerly, INC. | $191.11 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kowa Pharmaceuticals America, INC. | $169.71 | 2020-2023 | Livalo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.18 | 2020-2023 | Lifevest |
| Cardiofocus, INC. | $122.50 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $120.61 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Esperion Therapeutics, INC. | $119.92 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $114.56 | 2022-2024 | Farxiga |
| Novo Nordisk INC | $78.74 | 2025 | Ozempic |
| Cvrx, INC. | $49.81 | 2023 | Barostim Neo System |
| Amarin Pharma, INC. | $35.47 | 2020-2021 | |
| Biotronik INC. | $30.10 | 2019 | |
| Lilly USA, LLC | $23.33 | 2025 | Zepbound |
| Astellas Pharma US INC | $22.44 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $22.41 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $22.19 | 2021 | |
| Heartflow, INC. | $20.78 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.39 | 2019 | |
| Preventice Services, LLC | $18.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Urbandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.